Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Duke University et al v. Sandoz Inc.
Case Number:
1:18-cv-00997
Court:
Nature of Suit:
Judge:
Firms
- Fish & Richardson
- Goodwin Procter
- Greenberg Traurig
- Nixon Peabody
- O'Melveny & Myers
- Quarles & Brady
- Steptoe & Johnson PLLC
- Steptoe LLP
- Weil Gotshal
- Wheeler Trigg
Companies
Sectors & Industries:
-
September 22, 2023
Sandoz Can't Get New Trial After $39M Eyelash Serum IP Loss
A Colorado federal judge denied a new trial bid by Novartis' generic-drug making arm Sandoz over a patent covering a drug to grow eyelashes after a jury awarded $39 million to Allergan, rejecting the argument that the court erred in applying Federal Circuit precedent.
-
June 21, 2023
Sandoz Fights $39M Loss In Suit Over Eyelash Growth Serum
Novartis' generic-drug making arm wants another shot at persuading a federal jury in Colorado to wipe out a patent covering a drug developed by researchers at Duke University to grow eyelashes, arguing that the Federal Circuit already directly rejected some of the evidence behind the jury's $39 million verdict in favor of AbbVie, which makes the drug used in the product, Latisse.
-
May 02, 2023
Sandoz Drops Counterclaims After $39M Patent Trial Loss
Generic drug giant Sandoz Inc. has decided not to pursue its antitrust counterclaims against brand-name drug company Allergan, at least for now, after a federal jury in Colorado awarded $39 million against the generic drug maker for infringing a patent for eyelash growth drug Latisse.
-
April 11, 2023
Allergan To Get Bulk Of $39M Drug Patent Win Over Sandoz
Allergan and Duke University told a Colorado federal judge how they plan to split a recent $39 million verdict in their patent suit against generic drugmaker Sandoz, with Allergan getting almost all of the award.
-
March 31, 2023
Jury Says Sandoz Owes $39M For Eyelash Drug Infringement
Sandoz is liable for $39 million to Duke University and Allergan for infringing their patent for an eyelash-growth drug, a Colorado federal jury found Friday, upholding the patent's validity.
-
March 28, 2023
Allergan Drops Willfulness Allegation In Eyelash Drug Suit
Duke University and Allergan on Tuesday abandoned their allegation that Sandoz willfully infringed Duke's patent for eyelash growth drug Latisse, with a lawyer for Duke and Allergan stating that the issue had "become the tail wagging the dog" in the case.
-
March 27, 2023
Novartis Co. 'Jumped The Gun' With Eyelash Drug, Jury Told
Novartis subsidiary Sandoz Inc. ripped off a drug invented by Duke University researchers and licensed to drug company Allergan knowing that the school's patent for the drug would be approved, Duke and Allergan told a federal jury in Colorado on Monday.